Nitin Jain, MD, on Targeted Treatments and Tumor-Lysis Syndrome
Posted: Monday, September 30, 2019
What steps do you take to prevent tumor-lysis syndrome associated with targeted agents in CLL such as idelalisib, ibrutinib, and venetoclax?
Chronic Lymphocytic Leukemia Coverage from Every Angle
